A Phase 2 Open-label, Single-arm, Multicenter Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Refractory and Relapsed Multiple Myeloma
Latest Information Update: 26 Aug 2021
Price :
$35 *
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; MP 0250 (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms MiRRoR
- Sponsors Molecular Partners AG
- 14 Jan 2021 Status changed from active, no longer recruiting to completed.
- 06 Nov 2020 This trial is completed in Czech Republic, according to European Clinical Trials Database record.
- 22 Oct 2020 Planned End Date changed from 30 Jul 2023 to 15 Jan 2021.